一项评估 DISP-10 在晚期胃肠道癌症患者中的 1 期研究
一项评估DISP-10在晚期胃肠道癌症参与者中的安全性和有效性的I期研究
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Dispatch Clinical
- 电话号码:(215) 792-4699
- 邮箱:clinicaltrials@dispatchbio.com
学习地点
-
-
California
-
Duarte、California、美国、91010
- 招聘中
- City of Hope
-
Newport Beach、California、美国、92663
- 招聘中
- Hoag Memorial Hospital Presbyterian
-
-
Florida
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
-
Ohio
-
Cincinnati、Ohio、美国、45267
- 招聘中
- University of Cincinnati Cancer Center
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 尚未招聘
- Tennessee Oncology
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, colorectal adenocarcinoma, or biliary tract carcinoma
- Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Aged ≥18 years at time of signing informed consent
- Adequate organ function
Key Exclusion Criteria:
- Previous solid organ or hematopoietic cell transplant
- Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy
- Known history of hepatitis B or HIV infection
- Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment
- Known active central nervous system (CNS) metastases
- Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis
- Active treatment with antiviral agents
- History of severe hypersensitivity to fludarabine or cyclophosphamide
- Prior therapies/treatments with oncolytic viruses or T cell derived cellular therapy
Additional criteria apply and should be discussed with the study site.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:DISP-10
Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Treatment Emergent Adverse Events (TEAEs)
大体时间:90 days (2 years for related Serious Adverse Events)
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
90 days (2 years for related Serious Adverse Events)
|
|
Incidence of Dose Limiting Toxicities (DLTs) [PART 1]
大体时间:28 days
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
28 days
|
|
Identification of the Recommended Dose for Expansion (RDE) [PART 1]
大体时间:Up to 2 years
|
To select the Recommended Dose for Expansion (RDE) for Part 2 |
Up to 2 years
|
|
Overall response rate (ORR) [PART 2]
大体时间:Up to 2 years
|
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1 |
Up to 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall response rate (ORR) [PART 1]
大体时间:Up to 2 years
|
Confirmed CR or PR, per RECIST v1.1 |
Up to 2 years
|
|
Disease control rate (DCR)
大体时间:Up to 2 years
|
Proportion of participants with CR, PR, or stable disease per RECIST v1.1 |
Up to 2 years
|
|
Duration of response (DOR)
大体时间:Up to 2 years
|
Time from CR or PR to radiographic progression or death |
Up to 2 years
|
|
Progression Free Survival (PFS)
大体时间:Up to 2 years
|
Time from ide-cel administration to disease progression or death, whichever occurs first |
Up to 2 years
|
|
Overall survival (OS)
大体时间:Up to 15 years
|
Time from ide-cel administration to death |
Up to 15 years
|
|
Time to response (TTR)
大体时间:Up to 2 years
|
Time from ide-cel administration to the first documentation of objective tumor response |
Up to 2 years
|
|
Cellular kinetics (CK) of ide-cel
大体时间:Up to 2 years
|
Measurement of ide-cel CK in the blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Cmax
大体时间:Up to 2 years
|
Maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Tmax
大体时间:Up to 2 years
|
Time to maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - AUC
大体时间:Up to 2 years
|
Area under the blood concentration curve |
Up to 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.